I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| T cell | 6 studies | 27% ± 5% | |
| B cell | 5 studies | 23% ± 4% | |
| plasmablast | 5 studies | 31% ± 16% | |
| endothelial cell | 5 studies | 22% ± 7% | |
| ciliated cell | 5 studies | 25% ± 15% | |
| natural killer cell | 5 studies | 27% ± 9% | |
| CD4-positive, alpha-beta T cell | 5 studies | 26% ± 6% | |
| hematopoietic precursor cell | 4 studies | 23% ± 7% | |
| epithelial cell | 4 studies | 31% ± 10% | |
| pro-B cell | 4 studies | 28% ± 7% | |
| basal cell | 4 studies | 22% ± 5% | |
| CD8-positive, alpha-beta T cell | 4 studies | 30% ± 3% | |
| connective tissue cell | 3 studies | 17% ± 0% | |
| abnormal cell | 3 studies | 19% ± 2% | |
| neural crest cell | 3 studies | 32% ± 10% | |
| neuron | 3 studies | 17% ± 0% | |
| GABAergic neuron | 3 studies | 23% ± 4% | |
| glutamatergic neuron | 3 studies | 26% ± 7% | |
| transit amplifying cell | 3 studies | 35% ± 10% | |
| erythroblast | 3 studies | 42% ± 21% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 24% ± 5% |
